BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity of cell culture transferrin production by up to 40%.

Stephane Argivier, BBI’s Director of Product Management said “demand for our cell culture grade transferrin was growing at such a rate that we had reached our full capacity. In response to market demand we saw the opportunity to increase our capacity to meet the needs of our customers and provide room for growth.”

Human transferrin is a natural and often essential component to promote cell growth in many cell culture applications and is frequently used in serum free media, where it acts as an iron transporter.

BBI have been manufacturing human holo, apo and sidero grades of transferrin for over 10 years. In this time, growth in the cell culture market has been noticeable and it is only set to continue, as forecasts show it to be worth 18.63 Billion USD by 2020 (CAGR 10.5%)¹.

Factors triggering growth include increasing incidence of chronic diseases, increasing regulatory approvals for cell culture based vaccines, funding for cell-based research and technological advancements in cell culture products¹.

The increase in BBI’s production capacity has seen substantial improvements to the manufacturing facilities at their site in Sittingbourne, England. Investing £150K into new machinery, and increasing resource capabilities.

BBI’s human transferrin is manufactured under the ISO 13485 quality management system. BBI provide high specification material at large scale and with excellent batch-to-batch consistency. The human transferrin is pasteurised and filtered at 0.2µm to guarantee low mycoplasma and low bioburden. BBI can also control many other parameters, such as moisture and iron levels, to meet customer’s specifications and requirements.

To find out more about BBI’s native transferrin range visit www.bbisolutions.com or call +44 (0) 2920 747 232 to order a sample.


The Future of Pathology: Landmark initiative to spark conversation between pathology community and healthcare leaders

International panel of pathologists drive forward-thinking agenda on role of pathology in transformi...

Read More >

OGT expands direct sales and support infrastructure in Europe

Customers to benefit from Sysmex’s extensive operational footprint

Read More >

EKF Publishes Guide to Good Capillary Blood Sampling

Incorrect capillary blood sampling is most common reason for inaccurate POC hemoglobin results

Read More >

EKF Quo-Test® supports improved medical management of diabetic retinopathy patients

POC HbA1c study at Great Western Hospitals NHS Foundation Trust is finalist for 2019 RCOphth/Bausch...

Read More >

IPP signs a significant deal with BBI Solutions on Ginolis LFDA assembly line delivery

Industrial Production Processes (IPP) Ltd today announced that it has signed a contract with BBI Sol...

Read More >

MBM and OCB launch ColoProg in China on March 7th 2018

Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cance...

Read More >